Takeda’s Entyvio: benefit of real-world data in GI diseases
Takeda has published promising real-world data for its UC and CD drug Entyvio,...
Focus:
Most Read
Latest Content
Takeda’s SC Entyvio meets primary endpoint in Crohn’s Disease
At the European Crohn’s and Colitis Organization (ECCO) congress in Vienna, Austria, Takeda announced the subcutaneous (SC) formulation of Entyvio (vedolizumab) met its primary endpoint in Crohn’s Disease.
Takeda’s Entyvio: benefit of real-world data in GI diseases
Takeda has published promising real-world data for its UC and CD drug Entyvio, which suggest the drug is better tolerated by patients than four anti-TNFα therapies. Takeda’s Global Gastroenterology Outcomes Research head Michelle Luo explains the results of the study and the benefits of real world studies for patients with these gastrointestinal diseases.
FDA approves Janssen’s Stelara for adults with UC
Johnson & Johnson (J&J) subsidiary Janssen has announced the US Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for adults with moderately and severely active ulcerative colitis (UC).
Cheplapharm to acquire Losec’s global commercial rights for $243m
German pharmaceutical company Cheplapharm Arzneimittel has signed an agreement to purchase global commercial rights for Losec (omeprazole) from AstraZeneca for $243m.
FDA investigating Zantac for carcinogenic chemicals
Zantac tablets have been found to contain 26,000 times the FDA-approved amount of NDMA (a cancer-causing chemical) that can be safely consumed daily.
FDA to review ranitidine after detecting cancer-causing contamination
The US Food and Drug Administration (FDA) has issued a statement regarding the safety of the drug ranitidine after the detection of N-nitrosodimethylamine (NDMA) in some samples.
Takeda submits NDA for SC formation of ulcerative colitis treatment
Takeda Pharmaceutical has submitted a new drug application (NDA) in Japan for a subcutaneous (SC) formulation of vedolizumab to treat adults with moderately to severely active ulcerative colitis (UC).
Takeda takes a step forward in becoming dominant player in IBD landscape
The Japanese drugmaker intends to make Entyvio available in both a pre-filled syringe as well as a pen to add to its currently approved intravenous formulation.
Will value-based pricing be a trump card for Takeda’s Alofisel?
GlobalData expects new pricing scheme will provide Takeda greater clout to negotiate with the cost-conscious authorities of the EU.
Risk of ulcerative colitis increases in old age for young adults with a low body mass index
Low BMI in young men was associated with an increased risk of UC in a 40-year follow-up study.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top